Early epigenetic cancer decisions

References

Banito, A., Rashid, S.T., Acosta, J.C., Li, S., Pereira, C.F., Geti, I., Pinho, S., Silva, J.C., Azuara, V., Walsh, M., et al. (2009). Senescence impairs successful reprogramming to pluripotent stem cells. Genes Dev. 23, 2134–2139.10.1101/gad.1811609Search in Google Scholar PubMed PubMed Central

Boxer, R.B., Jang, J.W., Sintasath, L., and Chodosh, L.A. (2004). Lack of sustained regression of c-MYC-induced mammary adenocarcinomas following brief or prolonged MYC inactivation. Cancer Cell 6, 577–586.10.1016/j.ccr.2004.10.013Search in Google Scholar PubMed

Corbin, A.S., Agarwal, A., Loriaux, M., Cortes, J., Deininger, M.W., and Druker, B.J. (2011). Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J. Clin. Invest. 121, 396–409.10.1172/JCI35721Search in Google Scholar PubMed PubMed Central

Chabner, B.A. and Roberts, T.G., Jr. (2005). Timeline: chemotherapy and the war on cancer. Nat. Rev. Cancer 5, 65–72.10.1038/nrc1529Search in Google Scholar PubMed

Chin, L., Tam, A., Pomerantz, J., Wong, M., Holash, J., Bardeesy, N., Shen, Q., O’Hagan, R., Pantginis, J., Zhou, H., et al. (1999). Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472.10.1038/22788Search in Google Scholar PubMed

Chomel, J.C., Bonnet, M.L., Sorel, N., Bertrand, A., Meunier, M.C., Fichelson, S., Melkus, M., Bennaceur-Griscelli, A., Guilhot, F., and Turhan, A.G. (2011). Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood 118, 3657–3660.10.1182/blood-2011-02-335497Search in Google Scholar PubMed PubMed Central

Chu, S., McDonald, T., Lin, A., Chakraborty, S., Huang, Q., Snyder, D.S., and Bhatia, R. (2011). Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood 118, 5565–5572.10.1182/blood-2010-12-327437Search in Google Scholar PubMed PubMed Central

Etzioni, R., Urban, N., Ramsey, S., McIntosh, M., Schwartz, S., Reid, B., Radich, J., Anderson, G., and Hartwell, L. (2003). The case for early detection. Nat. Rev. Cancer 3, 243–252.10.1038/nrc1041Search in Google Scholar PubMed

Feinberg, A.P., Ohlsson, R., and Henikoff, S. (2006). The epigenetic progenitor origin of human cancer. Nature Rev. Genet. 7, 21–33.10.1038/nrg1748Search in Google Scholar PubMed

Hamilton, A., Helgason, G.V., Schemionek, M., Zhang, B., Myssina, S., Allan, E.K., Nicolini, F.E., Muller-Tidow, C., Bhatia, R., Brunton, V.G., et al. (2012). Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival. Blood 119, 1501–1510.10.1182/blood-2010-12-326843Search in Google Scholar PubMed PubMed Central

Hanahan, D. and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 646–674.10.1016/j.cell.2011.02.013Search in Google Scholar PubMed

Hong, H., Takahashi, K., Ichisaka, T., Aoi, T., Kanagawa, O., Nakagawa, M., Okita, K., and Yamanaka, S. (2009). Suppression of induced pluripotent stem cell generation by the p53-p21 pathway. Nature 460, 1132–1135.10.1038/nature08235Search in Google Scholar PubMed PubMed Central

Huettner, C.S., Zhang, P., Van Etten, R.A., and Tenen, D.G. (2000). Reversibility of acute B-cell leukaemia induced by BCR-ABL1. Nat. Genet. 24, 57–60.10.1038/71691Search in Google Scholar PubMed

Huff, C.A., Matsui, W., Smith, B.D., and Jones, R.J. (2006). The paradox of response and survival in cancer therapeutics. Blood 107, 431–434.10.1182/blood-2005-06-2517Search in Google Scholar PubMed PubMed Central

Iacobuzio-Donahue, C.A. (2009). Epigenetic changes in cancer. Annu. Rev. Pathol. 4, 229–249.10.1146/annurev.pathol.3.121806.151442Search in Google Scholar PubMed

Kawamura, T., Suzuki, J., Wang, Y.V., Menendez, S., Morera, L.B., Raya, A., Wahl, G.M., and Izpisua Belmonte, J.C. (2009). Linking the p53 tumour suppressor pathway to somatic cell reprogramming. Nature 460, 1140–1144.10.1038/nature08311Search in Google Scholar PubMed PubMed Central

Koeffler, H.P. and Golde, D.W. (1981a). Chronic myelogenous leukemia – new concepts (first of two parts). N. Engl. J. Med. 304, 1201–1209.10.1056/NEJM198105143042004Search in Google Scholar PubMed

Koeffler, H.P. and Golde, D.W. (1981b). Chronic myelogenous leukemia – new concepts (second of two parts). N. Engl. J. Med. 304, 1269–1274.10.1056/NEJM198105213042105Search in Google Scholar PubMed

Krizhanovsky, V. and Lowe, S.W. (2009). Stem cells: the promises and perils of p53. Nature 460, 1085–1086.10.1038/4601085aSearch in Google Scholar PubMed PubMed Central

Kumari, A., Brendel, C., Hochhaus, A., Neubauer, A., and Burchert, A. (2012). Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib. Blood 119, 530–539.10.1182/blood-2010-08-303495Search in Google Scholar PubMed

Li, H., Collado, M., Villasante, A., Strati, K., Ortega, S., Canamero, M., Blasco, M.A., and Serrano, M. (2009). The Ink4/Arf locus is a barrier for iPS cell reprogramming. Nature 460, 1136–1139.10.1038/nature08290Search in Google Scholar PubMed PubMed Central

Marion, R.M., Strati, K., Li, H., Murga, M., Blanco, R., Ortega, S., Fernandez-Capetillo, O., Serrano, M., and Blasco, M.A. (2009). A p53-mediated DNA damage response limits reprogramming to ensure iPS cell genomic integrity. Nature 460, 1149–1153.10.1038/nature08287Search in Google Scholar PubMed PubMed Central

Melo, J.V. and Barnes, D.J. (2007). Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat. Rev. Cancer 7, 441–453.10.1038/nrc2147Search in Google Scholar PubMed

Pardal, R., Clarke, M.F., and Morrison, S.J. (2003). Applying the principles of stem-cell biology to cancer. Nat. Rev. Cancer 3, 895–902.10.1038/nrc1232Search in Google Scholar PubMed

Perez-Caro, M., Cobaleda, C., Gonzalez-Herrero, I., Vicente-Duenas, C., Bermejo-Rodriguez, C., Sanchez-Beato, M., Orfao, A., Pintado, B., Flores, T., Sanchez-Martin, M., et al. (2009). Cancer induction by restriction of oncogene expression to the stem cell compartment. EMBO J. 28, 8–20.10.1038/emboj.2008.253Search in Google Scholar PubMed PubMed Central

Perez-Losada, J. and Balmain, A. (2003). Stem-cell hierarchy in skin cancer. Nat. Rev. Cancer 3, 434–443.10.1038/nrc1095Search in Google Scholar PubMed

Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105–111.10.1038/35102167Search in Google Scholar PubMed

Romero-Camarero, I., Jiang, X., Natkunam, Y., Lu, X., Vicente-Duenas, C., Gonzalez-Herrero, I., Flores, T., Luis Garcia, J., McNamara, G., Kunder, C., et al. (2013). Germinal centre protein HGAL promotes lymphoid hyperplasia and amyloidosis via BCR-mediated Syk activation. Nature Commun. 4, 1338.10.1038/ncomms2334Search in Google Scholar PubMed PubMed Central

Utikal, J., Polo, J.M., Stadtfeld, M., Maherali, N., Kulalert, W., Walsh, R.M., Khalil, A., Rheinwald, J.G., and Hochedlinger, K. (2009). Immortalization eliminates a roadblock during cellular reprogramming into iPS cells. Nature 460, 1145–1148.10.1038/nature08285Search in Google Scholar PubMed PubMed Central

Velasco-Hernandez, T., Vicente-Duenas, C., Sanchez-Garcia, I., and Martin-Zanca, D. (2012). p53 restoration kills primitive leukemia cells in vivo and increases survival of leukemic mice. Cell Cycle 12, 122–132.10.4161/cc.23031Search in Google Scholar PubMed PubMed Central

Vicente-Duenas, C., Fontan, L., Gonzalez-Herrero, I., Romero-Camarero, I., Segura, V., Aznar, M.A., Alonso-Escudero, E., Campos-Sanchez, E., Ruiz-Roca, L., Barajas-Diego, M., et al. (2012a). Expression of MALT1 oncogene in hematopoietic stem/progenitor cells recapitulates the pathogenesis of human lymphoma in mice. Proc. Natl. Acad. Sci. USA 109, 10534–10539.10.1073/pnas.1204127109Search in Google Scholar PubMed PubMed Central

Vicente-Duenas, C., Gonzalez-Herrero, I., Cenador, M.B., Criado, F.J., and Sanchez-Garcia, I. (2012b). Loss of p53 exacerbates multiple myeloma phenotype by facilitating the reprogramming of hematopoietic stem/progenitor cells to malignant plasma cells by MafB. Cell Cycle 11, 3896–3900.10.4161/cc.22186Search in Google Scholar PubMed PubMed Central

Vicente-Duenas, C., Romero-Camarero, I., Cobaleda, C., and Sanchez-Garcia, I. (2013). Function of oncogenes in cancer development: a changing paradigm. EMBO J. 32, 1502–1513.10.1038/emboj.2013.97Search in Google Scholar PubMed PubMed Central

Vicente-Duenas, C., Hauer, J., Ruiz-Roca, L., Ingenhag, D., Rodriguez-Meira, A., Auer, F., Borkhardt, A., and Sanchez-Garcia, I. (2014). Tumoral stem cell reprogramming as a driver of cancer: Theory, biological models, implications in cancer therapy. Semin Cancer Biol.Search in Google Scholar

Vicente-Duenas, C., Romero-Camarero, I., Gonzalez-Herrero, I., Alonso-Escudero, E., Abollo-Jimenez, F., Jiang, X., Gutierrez, N.C., Orfao, A., Marin, N., Villar, L.M., et al. (2012c). A novel molecular mechanism involved in multiple myeloma development revealed by targeting MafB to haematopoietic progenitors. EMBO J. 31, 3704–3717.10.1038/emboj.2012.227Search in Google Scholar PubMed PubMed Central

Weinstein, I.B. (2002). Cancer. Addiction to oncogenes – the Achilles heel of cancer. Science 297, 63–64.10.1126/science.1073096Search in Google Scholar PubMed

Zhao, Y., Yin, X., Qin, H., Zhu, F., Liu, H., Yang, W., Zhang, Q., Xiang, C., Hou, P., Song, Z., et al. (2008). Two supporting factors greatly improve the efficiency of human iPSC generation. Cell Stem Cell 3, 475–479.10.1016/j.stem.2008.10.002Search in Google Scholar PubMed